Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining tuberculin skin test with follow-on interferon gamma release assay markedly improves screening of household contacts.

Thorax·2025
Same author

Ambient PM<sub>2.5</sub> exposure and tuberculosis reactivation: a cross-sectional study in an intermediate burden city.

Epidemiology and infection·2025
Same author

No increased risk of tuberculosis-related immune reconstitution inflammatory syndrome with integrase inhibitor-based antiretroviral therapy in people with HIV with profound immunosuppression.

HIV medicine·2024
Same author

Association of smoking cessation with airflow obstruction in workers with silicosis: A cohort study.

PloS one·2024
Same author

Use of spirometry to detect airflow obstruction.

Respirology (Carlton, Vic.)·2024
Same author

Association of ambient PM<sub>2.5</sub> concentration with tuberculosis reactivation diseases-an integrated spatio-temporal analysis.

IJID regions·2023

Related Experiment Video

Updated: Jul 19, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Antituberculosis drugs and hepatotoxicity.

Wing Wai Yew1, Chi Chiu Leung

  • 1Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China. yewww@ha.org.hk

Respirology (Carlton, Vic.)
|October 21, 2006
PubMed
Summary

Antituberculosis drugs like isoniazid can cause liver damage, often linked to dose or hypersensitivity. Monitoring and patient education are crucial for managing drug-induced hepatotoxicity during TB treatment.

Area of Science:

  • Pharmacology
  • Hepatology
  • Infectious Diseases

Background:

  • Antituberculosis drugs, including isoniazid, pyrazinamide, and rifampicin, carry a risk of hepatotoxicity.
  • Hepatotoxic reactions can be dose-related or due to drug hypersensitivity.
  • Clinical risk factors include old age, malnutrition, alcoholism, HIV, and chronic hepatitis B/C.

Purpose of the Study:

  • To review the causes and risk factors of drug-induced hepatotoxicity during antituberculosis chemotherapy.
  • To emphasize the importance of clinical and biochemical monitoring for managing hepatotoxicity.
  • To discuss alternative drug regimens and monitoring strategies for latent TB infection.

Main Methods:

  • Review of literature on antituberculosis drug-induced hepatotoxicity.

Related Experiment Videos

Last Updated: Jul 19, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

  • Analysis of clinical risk factors and immunogenetic associations.
  • Discussion of monitoring strategies and alternative treatment options.

    • Main Results:

    • Hepatotoxicity often occurs early in antituberculosis chemotherapy.
    • Immunogenetics, particularly acetylator phenotype polymorphism, plays a role.
    • Risk factors significantly increase the likelihood of liver injury.

    Conclusions:

    • Vigilant clinical and biochemical monitoring is essential for patients undergoing antituberculosis chemotherapy.
    • Patient education on hepatitis symptoms is vital.
    • Alternative non-hepatotoxic drug regimens and careful monitoring are needed for latent TB infection, especially in at-risk individuals.